Larimar Therapeutics Inc (LRMR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $313.73M
Last updated: Nov 17, 2026 at 11:06 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 2.9% above its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 58.9, in the neutral range between 30 and 70.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about LRMR
News
LRMR Valuation
LRMR Profitability: Margins, ROIC and FCF
Larimar Therapeutics (LRMR) has an operating margin of 0.0% and a net margin of 0.0%.
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -139.6%
- FCF yield
- -74.2%
Larimar Therapeutics Competitors
The companies most similar to Larimar Therapeutics (LRMR) include Arcturus Therapeutics Holdings, Rocket Pharmaceuticals and Protara Therapeutics.
Sector: Healthcare
Companies most similar to Larimar TherapeuticsLRMR Analyst Ratings
Larimar Therapeutics (LRMR) has a Buy consensus from 11 analysts: 11 Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 11
- Strong Buy
- 2
- Buy
- 9
- Hold
- 0
- Sell
- 0
- Strong Sell
- 0
LRMR Bull Case vs Bear Case
Bull case
- 100.0% of LRMR's analyst ratings are Buy or Strong Buy.
Bear case
- LRMR beat EPS estimates in 37.5% of its last 8 reported quarters.
LRMR Earnings: Beat Rate and Next Report
Larimar Therapeutics (LRMR) beat the EPS estimate in 3 of the last 8 quarters (37.5%). Its next report is expected on Mar 17, 2027.
- Beat rate
- 3 of 8 quarters (37.5%)
- Average surprise
- -18.2%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.38
LRMR Earnings Date
LRMR reports Mar 17, 2027. The date is estimated.
LRMR ETF Holders
GNG tracks 7 ETFs that hold LRMR. The largest weights:
- Fidelity Enhanced Small Cap Core ETF (FESM), 0.04% of the fund
- iShares Biotechnology ETF (IBB), 0.01% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- Dimensional U.S. Core Equity 2 ETF (DFAC), <0.01% of the fund
Updated Nov 16, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About LRMR
When does LRMR report earnings?
Larimar Therapeutics Inc (LRMR) is expected to report earnings on Mar 17, 2027.
Does LRMR pay dividends?
Larimar Therapeutics Inc (LRMR) does not currently pay a regular dividend.
What is LRMR's market cap?
Larimar Therapeutics Inc (LRMR) has a market capitalization of $313.73M with a current stock price of $3.00.
LRMR pages: Overview, Earnings, Forecast, Financials, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.